| Previous close | 10.30 |
| Open | 10.30 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 10.30 - 10.30 |
| 52-week range | 9.62 - 14.48 |
| Volume | |
| Avg. volume | 416 |
| Market cap | 128.742M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | 32.19 |
| EPS (TTM) | 0.32 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 21.50 |
- Business Wire
Aelis Farma CEO Pier Vincenzo Piazza Receives the EY Entrepreneur of the Year Award
BORDEAUX, France, October 04, 2022--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS, PEA-PME eligible), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases, announces today that Pier Vincenzo Piazza, CEO of Aelis Farma, has received the Entrepreneur of the Year 2022 award from auditing and consulting firm Ernst and Young, in the "Scale-Up" category.
- Business Wire
Aelis Farma: Availability of the 2022 Half-year Financial Report
BORDEAUX, France, September 27, 2022--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 - ticker: AELIS, PEA-PME eligible), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases, today announces that its half-year financial report has been made available to the public and filled with the French Financial Markets Authority (Autorité des marchés financiers).
- Business Wire
Aelis Farma reports 2022 half-year financial results and confirms its development objectives
BORDEAUX, France, September 26, 2022--Regulatory News: Aelis Farma (Paris: AELIS)(ISIN: FR0014007ZB4 - ticker: AELIS, PEA-PME eligible), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases, today announces its half-year results for the period ended June 30, 2022 and takes stock of its development.
